Christelle Jouannaud

Christelle Jouannaud

Auto-generated profile, based on publicly available information

Christelle Jouannaud

Department of Medical Oncology, Institut Godinot , Reims

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FBFélix Balazard
Félix Balazard
ABAurelie Bertaut
Aurelie Bertaut
ÉBÉlise Bordet
Élise Bordet
SMStéphane Mulard
Stéphane Mulard
JBJulie Blanc
Julie Blanc
BPBarbara Pistilli
Barbara Pistilli
Background: Many patients receiving adjuvant endocrine therapy (ET) for breast cancer experience side effects and reduced quality of life (QoL) and discontinue ET. We sought to describe these issues and develop a prediction model of early discontinuation of ET. Methods: Among patients with hormone receptor–positive and HER2-negative stage I-III breast cancer of the Cancer Toxicities cohort (NCT01993498) who were prescribed adjuvant ET between 2012 and 2017, upon stratification by menopausal status, we evaluated adjuvant ET patterns including treatment change and patient-reported discontinuation and ET-associated toxicities and impact on QoL. Independent variables included clinical and demographic features, toxicities, and patient-reported outcomes. A machine-learning model to predict time to early discontinuation was trained and evaluated on a held-out validation set. Results: Patient-reported discontinuation rate of the first prescribed ET at 4 years was 30% and 35% in 4122 postmenopausal and 2087 premenopausal patients, respectively. Switching to a new ET was associated with higher symptom burden, poorer QoL, and higher discontinuation rate. Early discontinuation rate of adjuvant ET before treatment completion was 13% in postmenopausal and 15% in premenopausal patients. The early discontinuation model obtained a C index of 0.62 in the held-out validation set. Many aspects of QoL, most importantly fatigue and insomnia (European Organization for Research and Treatment of Cancer QoL questionnaire 30), were associated with early discontinuation. Conclusion: Tolerability and adherence to ET remains a challenge for patients who switch to a second ET. An early discontinuation model using patient-reported outcomes identifies patients likely to discontinue their adjuvant ET. Improved management of toxicities and novel more tolerable adjuvant ETs are needed for maintaining patients on treatment.

1 October 2021 in Current Oncology
Verified
Journal Article
Open access
PDF file
ECElsa CAUMETTE
Elsa CAUMETTE
IVInès Vaz-Luis
Inès Vaz-Luis
SPSandrine Pinto
Sandrine Pinto
JHJulie Havas
Julie Havas
TBThomas Bovagnet
Thomas Bovagnet
GMGwenn Menvielle
Gwenn Menvielle
Return to work (RTW) after breast cancer is associated with improved quality of life. The link between household characteristics and RTW remains largely unknown. The aim of this study was to examine the effect of the family situation on women’s RTW two years after breast cancer. We used data of a French prospective cohort of women diagnosed with stage I-III, primary breast cancer (CANTO, NCT01993498). Among women employed at diagnosis and under 57 years old, we assessed the association between household characteristics (living with a partner, marital status, number and age of economically dependent children, support by the partner) and RTW. Logistic regression models were adjusted for age, household income, stage, comorbidities, treatments and their side effects. Analyzes stratified by age and household income were performed to assess the association between household characteristics and RTW in specific subgroups. Among the 3004 patients included, women living with a partner returned less to work (OR = 0.63 [0.47–0.86]) and decreased their working time after RTW. Among the 2305 women living with a partner, being married was associated with decreased RTW among women aged over 50 (OR = 0.57 [0.34–0.95]). Having three or more children (vs. none) was associated with lower RTW among women with low household income (OR = 0.28 [0.10–0.80]). Household characteristics should be considered in addition to clinical information to identify vulnerable women, reduce the social consequence of cancer and improve their quality of life.

19 January 2022 in Reproductive BioMedicine Online
Verified
Journal Article
Closed access
MMManon MANGIARDI
Manon MANGIARDI
CSClara Sebbag
Clara Sebbag
CRChristine Rousset-Jablonski
Christine Rousset-Jablonski
IRIsabelle Ray-Coquard
Isabelle Ray-Coquard
CBClémentine Berkach
Clémentine Berkach
AHAnne Sophie Hamy
Anne Sophie Hamy

10 March 2022 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
ECElsa CAUMETTE
Elsa CAUMETTE
AMAntonio Di Meglio
Antonio Di Meglio
IVInès Vaz-Luis
Inès Vaz-Luis
CCCécile Charles
Cécile Charles
JHJulie Havas
Julie Havas
ADAgnes Dumas
Agnes Dumas

22 August 2017 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
ECElsa Curtit
Elsa Curtit
XPXavier. Pivot
Xavier. Pivot
JHJulie Henriques
Julie Henriques
SPSophie Paget-Bailly
Sophie Paget-Bailly
PFPierre Fumoleau
Pierre Fumoleau
DCDavid G. Cox
David G. Cox
Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effect of the 94 risk alleles can be calculated to measure the global risk of breast cancer. We aimed to test the hypothesis that the 94-SNP-based risk score is associated with clinico-pathological characteristics, breast cancer subtypes and outcomes in early breast cancer. A 94-SNP risk score was calculated in 8703 patients in the PHARE and SIGNAL prospective case cohorts. This score is the total number of inherited risk alleles based on 94 selected SNPs. Clinical data and outcomes were prospectively registered. Genotyping was obtained from a GWAS. The median 94-SNP risk score in 8703 patients with early breast cancer was 77.5 (range: 58.1–97.6). The risk score was not associated with usual prognostic and predictive factors (age; tumor, node, metastasis (TNM) status; Scarff-Bloom-Richardson grade; inflammatory features; estrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 (HER2) status) and did not correlate with breast cancer subtypes. The 94-SNP risk score did not predict outcomes represented by overall survival or disease-free survival. In a prospective case cohort of 8703 patients, a risk score based on 94 SNPs was not associated with breast cancer characteristics, cancer subtypes, or patients’ outcomes. If we hypothesize that prognosis and subtypes of breast cancer are determined by constitutional genetic factors, our results suggest that a score based on breast cancer risk-associated SNPs is not associated with prognosis. PHARE cohort: NCT00381901, Sept. 26, 2006 – SIGNAL cohort: INCa RECF1098, Jan. 28, 2009

3 September 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
DPDaniele Presti
Daniele Presti
AMAntonio Di Meglio
Antonio Di Meglio
JHJulie Havas
Julie Havas
MPMartina Pagliuca
Martina Pagliuca
BCBianca Cheaib
Bianca Cheaib
FJFlorence Joly
Florence Joly
Background: Breast cancer (BC) survivors receiving adjuvant treatments often report clinically relevant cancer-related cognitive complaints (CRCC), which have a significant impact on quality of life. We aimed to develop a comprehensive model of prediction of CRCC, including clinical and serum inflammatory protein data. Methods: We included 9575 stage I-III BC patients from the CANTO cohort (NCT01993498). Data were collected at diagnosis, 2 (year-2), and 4 (year-4) years post-diagnosis. Outcome of interest was CRCC (cognitive dimension of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 questionnaire, score < 75/100) at year-2 and year-4. Serum inflammatory markers (IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IFNg, IL-1, IL1Ra, TNF-a, and CRP) were available in a subset of patients with hormone-receptor-positive BC. Multivariable logistic regression models assessed associations of baseline clinical and inflammatory variables with CRCC. Results: Rates of CRCC were 31% (diagnosis), 39% (year-2), and 37% (year-4). Baseline validated predictors of CRCC reported at year-2 were chemotherapy, pretreatment CRCC, pain, and fatigue; predictors of CRCC reported at year-4 were pretreatment CRCC, pain, and anxiety. Other clinically relevant factors associated with CRCC at both time points during model development were pretreatment insomnia, receipt of endocrine therapy, and younger age/premenopausal status. No significant associations were observed between inflammatory markers and CRCC. Conclusions: Approximately 1 in 3 BC survivors in this cohort reported CRCC at diagnosis, with this rate being stable until year-4 after diagnosis. Pretreatment symptom burden and chemotherapy were validated as risk factors for long-term CRCC. No associations between inflammatory markers and self-reported CRCC emerged from this study.